Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 10, 2020 | Chief Medical Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 20,108 | $9.46 | 177,193 | |
| Jun 22, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,500 | $13.85 | 48,187 | |
| Jun 22, 2015 | SVP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 20,500 | $13.85 | 27,687 | |
| Apr 06, 2021 | Chief Science Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,501 | -- | 448,617 | |
| Apr 06, 2021 | Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,501 | -- | 241,206 | |
| Jun 07, 2021 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,557 | $6.45 | 905,287 | |
| Jun 07, 2021 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,557 | -- | -- | |
| Apr 11, 2019 | Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,579 | -- | 150,346 | |
| Apr 11, 2019 | Chief Science Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,579 | -- | 458,847 | |
| Apr 11, 2019 | Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,579 | -- | 154,127 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.